BOSTON, June 16, 2014 /PRNewswire/ -- PAREXEL
International (NASDAQ: PRXL), a leading global biopharmaceutical
services organization, today announced the launch of a new version
of its industry standard ClinPhone® RTSM
services designed to help clients start clinical trials more
quickly. The leading edge randomization and trial supply
management (RTSM) solution has been used in more than 3,000 studies
involving over 400,000 sites and two million patients since
1993. Developed by PAREXEL Informatics, it is a key component
of the Perceptive MyTrials® platform,
an integrated suite of applications for managing clinical
trials.
Biopharmaceutical companies are increasingly seeking to make
drug development more efficient without compromising patient safety
or data quality. Efficiency is particularly critical at the
start of clinical trials, when clients must simultaneously initiate
a broad range of important activities such as patient screening,
enrollment and randomization, as well as drug dispensation and
supply distribution.
Addressing these issues, ClinPhone® RTSM
can be more rapidly implemented using pre-built, interactive web
modules for patient, supply and site activities common to every
study. PAREXEL Informatics can also streamline system review and
approval for clients via an efficient visual design approach.
"Based upon our experience across thousands of studies, we have
identified ways to standardize common functionality for patient
screening, medication re-supply and other fundamental study
activities," said Xavier Flinois, President of PAREXEL Informatics.
"Our customers can simplify trial management activities, and
ultimately start their trials more quickly, using our powerful and
flexible RTSM technology."
"There is a growing need for faster, more efficient clinical
trials, yet conducting them has become increasingly complex," said
Mark A. Goldberg, M.D., President
and Chief Operating Officer, PAREXEL. "Trial success often hinges
on start-up speed and effectiveness. At PAREXEL, we view drug
development as a journey, and have made considerable investments in
developing cutting-edge technology to help simplify it from
beginning to end."
ClinPhone® RTSM is available through the
Perceptive MyTrials® platform and as a
standalone solution. ClinPhone® RTSM and
the Perceptive MyTrials® platform are also
available through the Perceptive® Partner
Program. For more information and a demonstration, visit PAREXEL
booth #1823 at the 50th Annual Drug Information
Association (DIA) Meeting, June 15-19,
2014 in San Diego.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 75 locations in 50
countries around the world, and has approximately 15,335
employees. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL, Perceptive, Perceptive MyTrials, ClinPhone, and "Your
Journey. Our Mission." are trademarks or registered trademarks
of PAREXEL International Corporation or its affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any
statements contained herein that are not statements of historical
fact may be deemed forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates,"
"plans," "expects," "intends," "appears," "estimates," "projects,"
"will," "would," "could," "should," "targets," and similar
expressions are also intended to identify forward-looking
statements. The forward-looking statements in this release
involve a number of risks and uncertainties. The Company's
actual future results may differ significantly from the results
discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON Group Ltd., Inc., or enter into new lines of
business; the impact on the Company's business of government
regulation of the drug, medical device and biotechnology
industry; consolidation within the pharmaceutical industry and
competition within the biopharmaceutical services industry; the
potential for significant liability to clients and third parties;
the potential adverse impact of health care reform; and the effects
of exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2014 as filed with the
Securities and Exchange Commission (SEC) on May 2, 2014, which "Risk Factors" discussion is
incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International